US Pharm. 2010;35(2):8.
New York/London — Chief Executive Andrew Witty of GlaxoSmithKline (GSK) has announced that the company will offer free access to a stock of 13,500 potential malaria treatments to the scientific and research community, including other pharmaceutical companies, to investigate further. GSK is developing a malaria vaccine and promises to seek only a small 5% profit and ensure that the vaccine is widely available, especially in Africa and Asia. Currently in phase III clinical trials, the Mosquirix vaccine, if approved, would be the first to protect against infection with mosquito-borne parasites that cause malaria. Over 1 million people worldwide die from the disease each year. “We must…ensure that we do not do anything which would discourage other companies from entering into this field,” Witty said.